Evidence map›Paper›PMID 39367036›Full record

ArticleScientific reports2024

Design, synthesis, and biological evaluation of novel imidazole derivatives as analgesic and anti-inflammatory agents: experimental and molecular docking insights.

Gulam Muheyuddeen, Mohd Yaqub Khan, Tanzeem Ahmad, Shriyansh Srivastava, Stuti Verma, Mo Suheb Ansari, Nilanchala Sahu

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. FeACS omega · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Gulam MuheyuddeenDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Jahangirabad Institute of Technology, Jahangirabad Fort, Jahangirabad, Barabanki, 225203, Uttar Pradesh, India. gulammuheyuddeen7860@gmail.com.ORCID http://orcid.org/0000-0001-6317-1630
Mohd Yaqub KhanDepartment of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, Taiwan.
Tanzeem AhmadDepartment of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India.
Shriyansh SrivastavaDepartment of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Stuti VermaDepartment of Pharmacy, Aryakul College of Pharmacy and Research, Sitapur Village, Jajjaur, Post, Manawa (Near Krishi Vigyan Kendra Sitapur) Sidhauli, Sitapur, Uttar Pradesh, India.
Mo Suheb AnsariDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Jahangirabad Institute of Technology, Jahangirabad Fort, Jahangirabad, Barabanki, 225203, Uttar Pradesh, India.
Nilanchala SahuSharda School of Pharmacy, Sharda University, Greater Noida, 201310, Uttar Pradesh, India. nilanchalasahu24@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imidazole moieties exhibit a broad range of biological activities, including analgesic, anti-depressant, anticancer, anti-fungal, anti-tubercular, anti-inflammatory, antimicrobial, antiviral, and antifungal properties. In this study, we explored the use of Schiff base for the synthesis of new imidazole derivatives as anti-inflammatory and pain-relieving agents. A series of eight novel imidazole analogues (2a-h) were prepared in three steps with excellent yields. All compounds were characterized using IR, NMR, and mass spectral data. Their analgesic and anti-inflammatory activities were evaluated using hot plate and paw oedema methods. Compound 2 g (1-(2,3-dichlorophenyl)-2-(3-nitrophenyl)-4,5-diphenyl-1H-imidazole) showed significant analgesic activity (89% at 100 mg/kg b.w.), while compounds 2a (2-(2,6-dichlorophenyl)-1-(4-ethoxyphenyl)-4,5-diphenyl-1H-imidazole) and 2b (2-(2,3-dichlorophenyl)-1-(2-chlorophenyl)-4,5-diphenyl-1H-imidazole) exhibited good anti-inflammatory activity (100% at 100 mg/kg b.w.), comparable to diclofenac salt (100% at 50 mg/kg b.w.). Molecular docking studies were conducted using Schrödinger software version 2021-2, employing the OPLS4 force field for both receptor and ligand preparation. The results were visualized using molecular visualization software such as PyMOL. These studies revealed that compound 2g exhibited the highest binding affinity with the COX-2 receptor (-5.516 kcal/mol). Compound 2g formed three conventional hydrogen bonds with residues GLN-242 (bond length: 2.3 Å) and ARG-343 (bond lengths: 2.2 Å & 2.4 Å). This binding affinity was comparable to that of Diclofenac salt, which showed the highest binding affinity of -5.627 kcal/mol with the COX-2 receptor. Diclofenac salt formed two conventional hydrogen bonds with the residues ARG-344 (bond length: 2.0 Å) and TRP-140 (bond length: 1.7 Å). Later, molecular dynamic simulations confirmed the stable binding affinity of compound 2g with the protein. Furthermore, other compounds also demonstrated potential binding to the receptor-binding pocket region. The anti-inflammatory potential of the synthesized compounds was evaluated using the carrageenan-induced rat hind paw oedema model, while the analgesic potential was assessed using the hot plate method. These evaluations were conducted in comparison with Diclofenac sodium, serving as the standard compound. However, compound 2g stood out for its superior analgesic activity, as confirmed by in-vivo examination. These findings suggest that these novel imidazole derivatives have potential as anti-inflammatory and analgesic agents.

Indexed as

AnalgesicsAnti-Inflammatory AgentsDrug DesignImidazolesMolecular Docking SimulationAnimalsCyclooxygenase 2EdemaMaleMicePainRatsStructure-Activity RelationshipAnalgesicsAnti-Inflammatory AgentsCyclooxygenase 2ImidazolesAnalgesic activityAnti-inflammatory agentsCOX-2 inhibitionDiclofenac sodiumImidazole derivativesMolecular docking studiesSchiff base synthesis

Identifiers

PMID39367036
PMCPMC11452658

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.